Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for MeVis Medical Solutions AG's EV-to-OCF or its related term are showing as below:
FRA:M3V'
s EV-to-OCF Range Over the Past 10 Years
Min: 5.34 Med: 9.3 Max: 20.17
Current: 10.23
During the past 13 years, the highest EV-to-OCF of MeVis Medical Solutions AG was 20.17. The lowest was 5.34. And the median was 9.30.
FRA:M3V's EV-to-OCF is ranked worse than 53.88% of 683
companies
in the Healthcare Providers & Services industry
Industry Median: 9.02
vs FRA:M3V: 10.23
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
MeVis Medical Solutions AG (FRA:M3V) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
MeVis Medical Solutions AG's PE Ratio (TTM) for today is calculated as:
MeVis Medical Solutions AG's share price for today is €23.80.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. MeVis Medical Solutions AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €0.419.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
MeVis Medical Solutions AG EV-to-OCF Related Terms
MeVis Medical Solutions AG EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, MeVis Medical Solutions AG's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MeVis Medical Solutions AG EV-to-OCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MeVis Medical Solutions AG's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where MeVis Medical Solutions AG's EV-to-OCF falls into.
MeVis Medical Solutions AG's current Enterprise Value is €40.40 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. MeVis Medical Solutions AG's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Is MeVis Medical Solutions AG (FRA:M3V) Overvalued in 2026?
Based on GuruFocus' analysis, MeVis Medical Solutions AG stock appears to be overvalued.
The current stock price of €23.80 is trading 6.7% above its estimated GF Value™ of €22.30.
GuruFocus considers MeVis Medical Solutions AG to be Fairly Valued.
Key valuation signals for FRA:M3V:
EV-to-OCF:
GF Value™: €22.30 vs. price of €23.80 (6.7% above fair value)
No single metric tells the full story. See the FRA:M3V stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MeVis Medical Solutions AG is a provider of medical software products. The company markets its products to equipment manufacturer of medical devices and providers of medical information technology platforms. Its segment includes Digital mammography and Other diagnostics. The Digital mammography segment develops and markets software products which assist in breast diagnostic imaging and intervention. Its Other diagnostics segment consists of digital radiology products. In addition, it also provides the general analysis of radiology images. The company's geographical area of operations includes the United States of America and Europe.
69GF Score
Get the complete analysis for FRA:M3V
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:M3V has been successfully added to your 
